International Journal of Cancer · 1996 · 51 citations · 25 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyImmunotherapy For Skin CancerMelanocytic TumorsTumor AntigensTumor-associated AntigensUveal MelanomaHla Class I MoleculesMage AntigensMelanoma ImmunotherapyMelanoma-associated AntigensMetastatic Uveal MelanomaPeptide-based ImmunotherapyUveal Melanoma MetastasisUveal Metastases
It has previously been reported that MAGE-1, -2, -3 and -4 genes are expressed in human cancers including cutaneous melanoma. MAGE-1 and MAGE-3 represent targets for specific immunotherapy because they encode peptide antigens which are recognised by cytotoxic T lymphocytes (CTL) when presented by HLA class I molecules, and pilot clinical trials with these peptides are currently in progress. It is likely that other members of the MAGE gene family may also encode antigens recognised by CTL. Uveal melanomas, like cutaneous melanomas, arise from melanocytes that are derived from the neural crest. To determine if uveal melanoma patients would be suitable for MAGE-peptide immunotherapy, the expression of MAGE-1, -2, -3 and -4 genes was assessed by reverse transcription followed by polymerase chain reaction (RT-PCR) amplification and ethidium bromide staining. Expression of MAGE genes was not detected in any of 27 primary tumours. Either MAGE-1 or MAGE-4 was expressed in only 2 of 26 metastatic samples, but expression of MAGE-2 or -3 was not detected. Our data suggest that, unlike cutaneous melanomas, uveal melanomas may not be suitable candidates for MAGE-peptide immunotherapy.
25
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
Pierre van der Bruggen, Catia Traversari, Patrick Chomez et al. · Science · 1991 · 3.5K citations
Life Sciences, Immunology, Oncology +17
Basic methods in molecular biology
Huntington Potter · Trends in Neurosciences · 1987 · 832 citations